Which statement about the approved RSV vaccines and monoclonal antibodies is true regarding their indicated age groups, use in pregnant individuals, and active versus passive immunization?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

RSV Vaccines and Monoclonal Antibodies: Key Distinctions

None of the three RSV vaccines are indicated for individuals 16 and older, and clesrovimab and nirsevimab are NOT vaccines—they are long-acting monoclonal antibodies for passive immunization of infants, not active vaccines.

Breaking Down Each Statement

Statement 1: "All three RSV vaccines indicated for individuals 16 and older"

FALSE. The three approved RSV vaccines are indicated for:

  • Adults ≥60 years (all three vaccines: Arexvy/RSVPreF3, Abrysvo/RSVpreF, and mResvia) 1
  • Adults 50-59 years at increased risk (RSVPreF3 only) 2
  • Adults ≥75 years (updated 2024 recommendation for all three) 1

There is no indication for the 16+ age group—this is a significant gap between pediatric protection (infants) and adult vaccination (50-60+ years).

Statement 2: "All three RSV vaccines indicated for high-risk individuals 18-59 years"

PARTIALLY FALSE. Only ONE vaccine (RSVPreF3/Arexvy) is indicated for adults aged 50-59 years at increased risk for RSV disease 2. The other two vaccines (Abrysvo and mResvia) are approved only for adults ≥60 years. None are indicated for the 18-49 age range.

Statement 3: "All three RSV vaccines indicated for pregnant individuals"

FALSE. Only ONE vaccine is indicated for pregnancy:

  • Abrysvo (RSVpreF) is approved for maternal immunization at 32-36 weeks' gestation to provide passive protection to infants through transplacental antibody transfer 3, 4
  • The other two vaccines (Arexvy/RSVPreF3 and mResvia) are NOT approved for use in pregnancy 2

This maternal vaccination provides passive protection to infants from birth through 6 months of age, not active immunization of the infant 2.

Statement 4: "Clesrovimab and nirsevimab are RSV vaccines"

DEFINITIVELY FALSE. This is a critical distinction:

Clesrovimab and nirsevimab are long-acting monoclonal antibodies, NOT vaccines 3:

  • They provide passive immunization (direct antibody administration)
  • They do NOT stimulate the infant's immune system to produce antibodies
  • They are administered directly to infants aged <8 months during or entering their first RSV season 3
  • Single dose provides protection for approximately 5 months (150 days) 3

The Correct Framework for RSV Prevention

For Infants (Birth to <8 months):

Three options exist, but only ONE should be used per infant 3:

  1. Maternal vaccination (Abrysvo at 32-36 weeks' gestation) → provides passive protection to infant
  2. Nirsevimab (monoclonal antibody) → given to infant
  3. Clesrovimab (monoclonal antibody) → given to infant (FDA approved June 2025) 3

Key principle: Either maternal vaccination OR infant monoclonal antibody—not both for most infants 3, 4.

For Adults:

  • Ages 50-59 at increased risk: RSVPreF3 only 2
  • Ages 60-74 at increased risk: Any of the three vaccines 1
  • Ages ≥75: All adults should receive vaccination 1

Common Pitfalls to Avoid

  1. Terminology confusion: Calling monoclonal antibodies "vaccines" is incorrect and confuses patients about active vs. passive immunization
  2. Age gap misunderstanding: There is NO RSV vaccine for ages 16-49 (except pregnant persons 18+ receiving maternal vaccine)
  3. Dual administration error: Most infants should receive EITHER maternal vaccine OR monoclonal antibody, not both 3, 4
  4. Pregnancy indication error: Only Abrysvo is approved for pregnancy; the other vaccines are contraindicated 2, 4

Clinical Decision Algorithm

For pregnant patients (32-36 weeks):

  • Delivering during RSV season (September-January in most US) → Consider maternal Abrysvo 4
  • If maternal vaccine given ≥14 days before birth → Infant protected, no monoclonal antibody needed 4
  • If maternal vaccine given <14 days before birth OR not given → Infant needs monoclonal antibody 4

For infants <8 months:

  • Mother vaccinated ≥14 days before birth → No additional protection needed 4
  • Mother not vaccinated OR unknown status → Give nirsevimab or clesrovimab 3
  • Born <34 weeks' gestation → Always give monoclonal antibody regardless of maternal vaccination 4

References

Related Questions

If the mother is unsure whether she received the RSV vaccine during pregnancy, should a 2‑month‑old infant receive RSV prophylaxis (e.g., nirsevimab) and what are the consequences of an extra dose of palivizumab (Synagis)?
What is the premise of using RSV‑specific antibodies for passive immunization, and what are the recommended first‑line and emerging prophylactic options?
What are the current recommendations for respiratory syncytial virus (RSV) prophylaxis and vaccination, including dosing frequency, for high‑risk infants and for adults aged 60 years and older?
Should RSV vaccination be given to the pregnant mother in the third trimester, or should RSV prophylaxis (nirsevimab) be administered to the newborn at birth?
What are the current RSV vaccination and prophylaxis recommendations for adults ≥60 years, pregnant individuals, immunocompromised patients, and high‑risk infants?
Which of the following statements is true regarding the approval of the two rapid‑acting insulin aspart biosimilar products: that ADEMELOG (insulin aspart) was the first rapid‑acting biosimilar approved, that both insulin aspart biosimilars were approved as interchangeable products, that both can be dosed via an insulin pump, or that neither contains new safety or efficacy data in their package inserts?
In a term pregnancy with pregnancy‑induced hypertension and a presumed placental abruption, under what conditions is expectant management appropriate?
What non‑controlled‑substance medication can be prescribed for insomnia, and should risperidone be administered in the morning rather than at night?
Which respiratory syncytial virus (RSV) vaccines are approved and recommended for adults aged 60 years and older?
In a patient with cirrhosis, an international normalized ratio of 2.1, and portal vein thrombosis, should therapeutic enoxaparin (low‑molecular‑weight heparin) at 1 mg/kg twice daily be initiated?
Which of the following statements is true: all three respiratory syncytial virus (RSV) vaccines are indicated to prevent lower respiratory tract disease in individuals aged 60 years and older, or all three RSV vaccines are indicated to prevent lower respiratory tract disease in high‑risk individuals aged 18–59 years?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.